AnaptysBio price target raised to $79 from $78 at Barclays

Barclays analyst Etzer Darout raised the firm’s price target on AnaptysBio (ANAB) to $79 from $78 and keeps an Overweight rating on the shares post the Q4 report. The firm sees progress toward the company’s’ planned Q2 separation and Jemperli royalty momentum.